News
Moon Shots Program
Since starting the Moon Shots Program® in 2012, we’ve made progress. And lots of it. Keep checking back here to stay up-to-date on the program’s achievements and see our latest innovations.
/cancermoonshots/about/news.html
According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed.
The trial results were...
In an effort to address a major challenge when analyzing large single-cell RNA-sequencing datasets, researchers from The University of Texas...
The University of Texas MD Anderson Cancer Center and UroGen Pharma Ltd. today announced a strategic three-year collaboration agreement to...
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic research collaboration and commercialization...
The North Texas A Conversation With a Living Legend® raised $1 million this week in a virtual version of the signature fundraising event benefiting...